Shionogi Stays The Course As It Lays Out R&D Priorities

Japan's Shionogi lays out its R&D priorities, with a continued strategic focus on anti-infectives and CNS drugs, saying it is looking for the approval of four molecules in the coming year.

Scientist
Shionogi Lays Out R&D Priorities • Source: Shutterstock

While Shionogi & Co. Ltd. fell one short of its goal of progressing three drug candidates in fiscal 2018 (ending March 2019), the mid-sized Japanese pharma company is still hoping to take its launch tally globally to at least 10 compounds (including those out-licensed) by the end of the fiscal 2017-20 period.

"Our challenge for 2019 will be to focus on high-priority projects, and maximize the value of in-licensed projects," president and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia